• Lung Cancer Group Cologne
  • Contact
  • Privacy Policy
  • English
    • Deutsch (German)
Netzwerk Genomische Medizin Lungenkrebs
  • Home
  • Health insurance companies
  • General information
  • Privacy Policy
  • Cookie Policy
  • Diagnostics
  • Hybrid-capture
  • Driver mutations
  • Fast-track analysis for first-line treatment
  • Driver mutations in lung cancer
  • Network Genomic Medicine – Lung Cancer
  • New therapeutic approaches from genomic research
  • New immunotherapeutic therapeutic approaches
  • Molecular Diagnostics
  • Contact
  • Imprint
  • Second Opinion service
  • Service invoicing
    • For pathologists
  • Map
  • Clinical trials
    • General information
    • Lung Cancer Study Group
    • What is a clinical trial?
    • Participation in a trial
  • The Network
    • Aims
    • Funding
    • Network Genomic Medicine cancer information system (NGMcis)
    • Publications
    • Related links
    • Our team
  • Ärzte
  • Veranstaltungen
Select Page

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer

Ramalingam SS, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Baudelet C, Lestini BJ, Rizvi NA

Journal: Int J Radiat Oncol Biol Phys
Published: December 1st, 2014

  • © 2016-2018 Network Genomic Medicine (NGM)
  • Contact
  • Imprint
  • Privacy Policy

Designed by Elegant Themes | Powered by WordPress